SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $580,350,212 |
| Positions | 36 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| LAKEFRONT BIOTHERAPEUTICS NV | LKFT | SPON ADR | $61,259,453 | 2,043,344 |
| JANUX THERAPEUTICS INC | JANX | COM | $58,436,828 | 3,804,481 |
| NEKTAR THERAPEUTICS | NKTR | COM NEW | $56,546,100 | 810,000 |
| BOSTON SCIENTIFIC CORP | BSX | COM | $54,215,252 | 1,270,273 |
| SHATTUCK LABS INC | STTK | COM | $41,347,666 | 5,957,877 |
| INSMED INC | INSM | COM PAR $.01 | $40,047,432 | 375,609 |
| ALNYLAM PHARMACEUTICALS INC | ALNY | COM | $29,525,022 | 98,080 |
| SYNDAX PHARMACEUTICALS INC | SNDX | COM | $26,232,000 | 1,200,000 |
| KURA ONCOLOGY INC | KURA | COM | $22,180,945 | 2,021,964 |
| ALKERMES PLC | ALKS | SHS | $20,664,012 | 394,389 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.